Skip to content

US · COLL · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Collegium Pharmaceutical, Inc. (COLL) intrinsic value and stock valuation

$24.72as of 2026-11-21 · Mkt cap 1.16B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Collegium Pharmaceutical, Inc. DCF and intrinsic value

InvestorsCraft values COLL with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from COLL’s statements →

Collegium Pharmaceutical, Inc. Graham Number

Graham Number: $20.60d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Stoughton, MA 02072 collegiumpharma.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$780.6M+20.3% 5y CAGRd
20132025
Net income
$62.9M+18.6% 5y CAGRd
20132025
Free cash flow
$327.6M
20132025
Total equity
$301.7M+10.2% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$780.6M$631.5M$566.8M$463.9M$276.9M
Operating income$187.1M$169.9M$167M$33.3M$17.6M
Net income$62.9M$69.2M$48.2M-$-25M$71.5M
EPSd$1.58M$1.71M$1.15M-$-738.99K$1.74M
Operating cash flow$329.3M$205M$274.8M$124.2M$103.6M
Capital expenditure-$-1.74M-$-1.65M-$-460K-$-1.62M-$-1.94M
Free cash flow$327.6M$203.3M$274.3M$122.6M$101.6M
Total assets$1.66B$1.66B$1.14B$1.17B$692.1M
Total debt$940.6M$859.3M$674.3M$709.2M$258.8M
Net debt$689.5M$788.7M$435.3M$535.5M$72.3M
Total equity$301.7M$228.8M$195.4M$194.8M$202.9M
Cash and short-term investments$406.5M$162.8M$310.6M$173.7M$186.4M
Income statement
20252024202320222021
Revenue$780.6M$631.5M$566.8M$463.9M$276.9M
Cost of revenue$317.3M$254.1M$240.6M$254.4M$126.3M
Gross profit$463.3M$377.3M$326.2M$209.5M$150.6M
Research and development expenses$0.00$0.00$0.00$3.98M$9.45M
Selling, general and administrative expenses$276.2M$183M$159.2M$172.2M$119M
Other expenses$0.00$24.5M$0.00$0.00$4.58M
Operating expenses$276.2M$207.5M$159.2M$176.2M$133M
Cost and expenses$593.5M$461.6M$399.8M$430.6M$259.2M
Interest income$11.3M$14M$15.6M$1.05M$10K
Interest expense$82.3M$74M$83.3M$63.2M$21M
Depreciation and amortization$226.1M$169.2M$149.3M$138.9M$68.9M
Ebitda$401M$341.7M$308.3M$173.3M$86.6M
Operating income$187.1M$169.9M$167M$33.3M$17.6M
Total other income/expenses, net-$-94.47M-$-71.33M-$-91.23M-$-62.17M-$-21M
Income before tax$92.6M$98.6M$75.7M-$-28.85M-$-3.37M
Income tax expense$29.8M$29.4M$27.6M-$-3.85M-$-74.89M
Net income$62.9M$69.2M$48.2M-$-25M$71.5M
Weighted average shares outstanding$31.7M$32.3M$33.7M$33.8M$34.9M
Weighted average diluted shares outstanding$39.7M$40.4M$41.8M$33.8M$41.1M
Balance sheet
20252024202320222021
Cash and short-term investments$406.5M$162.8M$310.6M$173.7M$186.4M
Net receivables$211.3M$228.5M$179.5M$183.1M$105.8M
Inventory$40.9M$35.6M$32.3M$46.5M$17.4M
Total current assets$691.4M$482.3M$537.6M$420M$315.5M
Property, plant and equipment, net$16.2M$20.2M$22M$26.4M$27.1M
Goodwill and intangible assets$815.4M$1.05B$555.6M$701.2M$268.7M
Long-term investments$1.06M$0.00$0.00$2.55M$2.55M
Total non-current assets$965.4M$1.18B$605.7M$754.1M$376.5M
Total assets$1.66B$1.66B$1.14B$1.17B$692.1M
Accounts payable$10.7M$3.93M$8.69M$3.49M$4.19M
Short-term debt$30.4M$65.9M$184.3M$163.6M$49.2M
Deferred revenue$670K$0.00$990K$0.00$0.00
Total current liabilities$440M$509.5M$457.9M$433.7M$279.6M
Long-term debt$910.2M$793.4M$490M$545.6M$209.6M
Deferred revenue, non-current$9.11M$10M$0.00$0.00$0.00
Total non-current liabilities$915.1M$925.2M$490M$545.6M$209.6M
Capital lease obligations$4.13M$6.81M$7.11M$8.22M$8.77M
Total liabilities$1.36B$1.43B$947.9M$979.3M$489.2M
Common stock$40K$40K$40K$40K$40K
Retained earnings-$-101.13M-$-164M-$-233.19M-$-281.34M-$-256.34M
Accumulated other comprehensive income (loss)$320K$60K$10K$0.00$0.00
Total equity$301.7M$228.8M$195.4M$194.8M$202.9M
Total investments$156.5M$92.2M$71.6M$2.55M$2.55M
Total debt$940.6M$859.3M$674.3M$709.2M$258.8M
Net debt$689.5M$788.7M$435.3M$535.5M$72.3M
Cash flow statement
20252024202320222021
Net income$62.9M$69.2M$48.2M-$-25M$71.5M
Depreciation and amortization$220.8M$169.2M$149.3M$138.9M$68.9M
Stock-based compensation$41.9M$32.4M$27.1M$22.9M$24.3M
Change in working capital$3.76M-$-54.98M$21.7M-$-12.71M$13.5M
Accounts receivable$17.2M-$-4.41M$3.59M-$-21.78M-$-22.52M
Inventory-$-5.35M$13.9M$14.2M$48.3M-$-2.3M
Accounts payable$6.72M-$-11.28M$5.06M-$-710K-$-5.83M
Net cash provided by operating activities$329.3M$205M$274.8M$124.2M$103.6M
Investments in property, plant and equipment-$-1.74M-$-1.65M-$-460K-$-1.62M-$-1.94M
Acquisitions, net$0.00-$-267.54M$0.00-$-572.07M$0.00
Net cash used for investing activities-$-63.53M-$-287.76M-$-70.81M-$-573.69M-$-1.94M
Common stock issued$5.64M$0.00$0.00$0.00$0.00
Common stock repurchased-$-25.1M-$-60.02M-$-75M-$-14.06M-$-47.86M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-110.25M-$-60.6M-$-140.18M$436.7M-$-89.3M
Net change in cash$155.6M-$-143.38M$63.8M-$-12.74M$12.3M
Cash at end of period$252.2M$96.6M$240M$176.2M$189M
Operating cash flow$329.3M$205M$274.8M$124.2M$103.6M
Capital expenditure-$-1.74M-$-1.65M-$-460K-$-1.62M-$-1.94M
Free cash flow$327.6M$203.3M$274.3M$122.6M$101.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Collegium Pharmaceutical, Inc.

        Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.

        CEO
        Vikram Karnani
        Employees
        423
        Beta
        0.73

        Explore

        Frequently asked questions

        What is the intrinsic value of Collegium Pharmaceutical, Inc. (COLL)?

        Collegium Pharmaceutical, Inc. (COLL) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is COLL undervalued?

        COLL trades at a price of $24.72 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.